Product Description
JNK3 (c-Jun N-terminal kinase 3), also known as MAPK10 (mitogen-activated protein kinase 10), is a member of the serine/threonine protein kinase family (MAPK subfamily) that plays a pivotal role in stress-induced neuronal apoptosis, neurodegenerative processes, and synaptic plasticity. JNK3 is activated by various stimuli including oxidative stress, excitotoxicity, amyloid-β, and ischemia, leading to phosphorylation of downstream targets such as c-Jun, ATF2, and ELK1, thereby regulating AP-1 transcriptional activity and promoting cell death signaling. Beyond its role in normal neuronal development and stress responses, dysregulation of JNK3 signaling—through hyperactivation or aberrant expression—is closely associated with neurodegenerative diseases (including Alzheimer's disease, Parkinson's disease, Huntington's disease), cerebral ischemia, epilepsy, and traumatic brain injury, making it a highly validated target for neuroprotective therapy and CNS drug discovery.
Screeningbio’s JNK3 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying JNK3 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: JNK3 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the JNK3 kinase.
Data